Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Author:
Affiliation:
1. Regeneron Pharmaceuticals Tarrytown NY USA
Funder
Sanofi
Regeneron Pharmaceuticals
Publisher
Wiley
Subject
Immunology,Immunology and Allergy
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14151
Reference70 articles.
1. The Cytokines of Asthma
2. Strategies targeting the IL-4/IL-13 axes in disease
3. Targeting key proximal drivers of type 2 inflammation in disease
4. Novel Biologicals for the Treatment of Allergic Diseases and Asthma
5. Commonality of the IL-4/IL-13 pathway in atopic diseases
Cited by 261 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Shegan-Mahuang decoction ameliorates cold-induced asthma via regulating the proliferation and apoptosis of airway smooth muscle cells through TAS2R10: An in vivo and in vitro study;Journal of Ethnopharmacology;2024-11
2. IgE plasma cells are transcriptionally and functionally distinct from other isotypes;Science Immunology;2024-09-06
3. Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation;iScience;2024-09
4. Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study;Respiratory Medicine;2024-09
5. Structural insight into interleukin‐4Rα and interleukin‐5 inhibition by nanobodies from a bispecific antibody;MedComm;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3